<h4>Background</h4>Lung cancer, characterized by its high global incidence and mortality rates, necessitates comprehensive and precise stratification strategies to guide the diverse diagnostic approaches and therapeutic agents in clinical decision-making.<h4>Objectives</h4>Shox2 and Rassf1a promoter methylation are established biomarkers for the early screening of lung cancer. This evidence concerns the gene SHOX2 and lung carcinoma.